Stock has got OUTPERFORM rating from no analyst of Thomson Reuters, 13 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Scotiabank reissued a "sector perform" rating and set a C$15.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, March 1st. Its last month's stock price volatility remained 15.67% which for the week stands at 23.34%. These analysts and investment firms use various valuation methods to decide a price target for a stock.
In case of Revenue Estimates, 297080 analysts have provided their consensus Average Revenue Estimates for Valeant Pharmaceuticals International, Inc.as 5000. Rodman & Renshaw lowered Valeant Pharmaceuticals Intl from a "buy" rating to a "neutral" rating in a research note on Tuesday, January 31st. Many traders and investors view the 52-week high or low as an important factor in determining a stock's current value and predicting future price movement. Morgan Stanley Maintains the stock to Overweight on 11/10/16 by stationing a price target of $25. Consensus earnings estimates are far from flawless, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock.
03/15/2017 - Valeant Pharmaceuticals International, Inc. had its " rating reiterated by analysts at Canaccord Genuity. (VRX) to Hold with no specific Price Target. They now have a United States dollars 45 price target on the stock. (VRX) has a mean recommendation of 3.18, according to data compiled by Zacks Investment Research. (VRX) where 3 analyst have rated the stock as Strong Buy, 0 analysts said it's a Buy, 13 rated the stock as Hold, 4 analysts reported Underperform and 0 analysts gave their recommendations as Sell.
Other analysts have also recently issued research reports about the stock. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell. American Group stated it has 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.06.
Relative strength index (RSI-14) for Valeant Pharmaceuticals International, Inc. During the same period in the previous year, the business earned $1.55 earnings per share.
Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock.
The meeting will be held on Tuesday, May 2, 2017 at 9:00 a.m. ET at the Company's offices located at 2150 Saint Elzear Blvd. The company has market cap of $3.41 billion. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), CAH stock's 10-day call/put volume ratio of 3.50 is just 9 percentage points from an annual high - suggesting a near-extreme preference for calls over puts. The firm's 50 day moving average price is $11.57 and its 200 day moving average price is $16.00.
On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance.
In the trailing 12 months period, return on assets ratio of the Company was -5.20% and return on equity ratio was -52.70% while its return on investment ratio was -1.60%.
The stock grew about 61.43% in the past 5 years, this positive value indicates that the stock constantly performed well in previous years as well. The company's year to date (YTD) performance is at -34.71%.
03/09/2017 - Valeant Pharmaceuticals International, Inc. had its " rating reiterated by analysts at Morgan Stanley. The last session's volume of 3.26 million shares was lower than its average volume of 3.81 million shares. The stock, after opening at $0.36, hit $0.41 through the close by scoring 6.18%. VRX's profit will be $338.05 million for 2.28 P/E if the $0.99 EPS becomes a reality.